OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez‐Ruiz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 170
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez‐Ruiz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 170
Showing 1-25 of 170 citing articles:
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 211
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 211
Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer Immunotherapy
Yunrong Yang, Jia Huang, Min Liu, et al.
Advanced Science (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 124
Yunrong Yang, Jia Huang, Min Liu, et al.
Advanced Science (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 124
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 91
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 91
HIF-1α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1
Zhou Yang, Wei Su, Xiyi Wei, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112945-112945
Open Access | Times Cited: 75
Zhou Yang, Wei Su, Xiyi Wei, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112945-112945
Open Access | Times Cited: 75
Oxygen Self-Generating Nanoreactor Mediated Ferroptosis Activation and Immunotherapy in Triple-Negative Breast Cancer
Ke Li, Kun Xu, Ye He, et al.
ACS Nano (2023) Vol. 17, Iss. 5, pp. 4667-4687
Closed Access | Times Cited: 71
Ke Li, Kun Xu, Ye He, et al.
ACS Nano (2023) Vol. 17, Iss. 5, pp. 4667-4687
Closed Access | Times Cited: 71
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine
Valentin Van den Bossche, Hannah Zaryouh, Marianela Vara-Messler, et al.
Drug Resistance Updates (2022) Vol. 60, pp. 100806-100806
Closed Access | Times Cited: 68
Valentin Van den Bossche, Hannah Zaryouh, Marianela Vara-Messler, et al.
Drug Resistance Updates (2022) Vol. 60, pp. 100806-100806
Closed Access | Times Cited: 68
Hypoxia signaling in cancer: Implications for therapeutic interventions
Yan Zhuang, Kua Liu, Qinyu He, et al.
MedComm (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 50
Yan Zhuang, Kua Liu, Qinyu He, et al.
MedComm (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 50
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
Veronica Finisguerra, Tereza Dvořáková, Matteo Formenti, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 5, pp. e005719-e005719
Open Access | Times Cited: 47
Veronica Finisguerra, Tereza Dvořáková, Matteo Formenti, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 5, pp. e005719-e005719
Open Access | Times Cited: 47
Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release
Jing Liu, Horacio Cabral, Peng Mi
Advanced Drug Delivery Reviews (2024) Vol. 207, pp. 115239-115239
Closed Access | Times Cited: 44
Jing Liu, Horacio Cabral, Peng Mi
Advanced Drug Delivery Reviews (2024) Vol. 207, pp. 115239-115239
Closed Access | Times Cited: 44
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance
Ting‐Wan Kao, Geng-Hao Bai, Tian‐Li Wang, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 42
Ting‐Wan Kao, Geng-Hao Bai, Tian‐Li Wang, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 42
Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy
Yuedong Guo, Ping Hu, Jianlin Shi
Journal of the American Chemical Society (2024) Vol. 146, Iss. 15, pp. 10217-10233
Closed Access | Times Cited: 33
Yuedong Guo, Ping Hu, Jianlin Shi
Journal of the American Chemical Society (2024) Vol. 146, Iss. 15, pp. 10217-10233
Closed Access | Times Cited: 33
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 21
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 21
Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief
Mengying He, Mengyao Zhang, Tao Xu, et al.
Journal of Controlled Release (2024) Vol. 368, pp. 233-250
Closed Access | Times Cited: 19
Mengying He, Mengyao Zhang, Tao Xu, et al.
Journal of Controlled Release (2024) Vol. 368, pp. 233-250
Closed Access | Times Cited: 19
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities
Qin Qin, Rong Yu, John Eriksson, et al.
Cancer Letters (2024) Vol. 591, pp. 216859-216859
Open Access | Times Cited: 16
Qin Qin, Rong Yu, John Eriksson, et al.
Cancer Letters (2024) Vol. 591, pp. 216859-216859
Open Access | Times Cited: 16
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 61
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 61
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
Manfei Pi, Huixian Kuang, Chunyan Yue, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100822-100822
Closed Access | Times Cited: 53
Manfei Pi, Huixian Kuang, Chunyan Yue, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100822-100822
Closed Access | Times Cited: 53
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications
Philippe Icard, Luca Simula, Ludovic Fournel, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100852-100852
Open Access | Times Cited: 39
Philippe Icard, Luca Simula, Ludovic Fournel, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100852-100852
Open Access | Times Cited: 39
Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies
Andrea Monti Hughes, Naonori Hu
Cancers (2023) Vol. 15, Iss. 16, pp. 4091-4091
Open Access | Times Cited: 32
Andrea Monti Hughes, Naonori Hu
Cancers (2023) Vol. 15, Iss. 16, pp. 4091-4091
Open Access | Times Cited: 32
Alleviating hypoxia to improve cancer immunotherapy
Peng Fan, Naidong Zhang, Eleonora Candi, et al.
Oncogene (2023) Vol. 42, Iss. 49, pp. 3591-3604
Closed Access | Times Cited: 31
Peng Fan, Naidong Zhang, Eleonora Candi, et al.
Oncogene (2023) Vol. 42, Iss. 49, pp. 3591-3604
Closed Access | Times Cited: 31
Mn3O4 Nanoshell Coated Metal–Organic Frameworks with Microenvironment‐Driven O2 Production and GSH Exhaustion Ability for Enhanced Chemodynamic and Photodynamic Cancer Therapies
Wenya Li, Rongtian Li, Qiang Ye, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 15
Closed Access | Times Cited: 25
Wenya Li, Rongtian Li, Qiang Ye, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 15
Closed Access | Times Cited: 25
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Yalan Zhang, Weilin Zhou, Jianping Yang, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Yalan Zhang, Weilin Zhou, Jianping Yang, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Notch signaling, hypoxia, and cancer
Mingzhou Guo, Yang Niu, Min Xie, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 24
Mingzhou Guo, Yang Niu, Min Xie, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 24
Nanomedicine Strategies in Conquering and Utilizing the Cancer Hypoxia Environment
Yi Pan, Longcai Liu, Xiaozhou Mou, et al.
ACS Nano (2023) Vol. 17, Iss. 21, pp. 20875-20924
Closed Access | Times Cited: 22
Yi Pan, Longcai Liu, Xiaozhou Mou, et al.
ACS Nano (2023) Vol. 17, Iss. 21, pp. 20875-20924
Closed Access | Times Cited: 22
A light-activatable theranostic combination for ratiometric hypoxia imaging and oxygen-deprived drug activity enhancement
Lei Ge, Yikai Tang, Chong‐Zhi Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Lei Ge, Yikai Tang, Chong‐Zhi Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
